Identifying Genes That Predict Risk of Developing Cervical Intraepithelial Neoplasia or Invasive Cervical Cancer

Overview

RATIONALE: Finding certain changes in genes may help doctors predict which patients are at risk of developing cervical intraepithelial neoplasia or invasive cervical cancer and may help the study of cancer in the future. PURPOSE: This clinical trial is studying genes that may predict which patients are at risk of developing cervical intraepithelial neoplasia or invasive cervical cancer.

Full Title of Study: “HIV-Associated DNA Hypermethylation in Cervical Cancer”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 2012

Detailed Description

OBJECTIVES: – Utilize molecular assays to identify a panel of hypermethylated genes that are predictive of cervical intraepithelial neoplasia (CIN) grade 3 or invasive cervical cancer (ICC) among patients with or without HIV infection. – Perform a nested case-control study assessing the risk of developing CIN3 in relationship to human papillomavirus (HPV) persistence, HIV, and the presence or acquisition of candidate hypermethylated genes in these patients. – Identify HIV-related factors (e.g., CD4 counts, viral load, and highly active antiretroviral therapy [HAART]) that might be associated with the presence or acquisition of specific hypermethylated genes in these patients. OUTLINE: This is a longitudinal, multicenter study. Patients undergo biopsy for removal of cervical tissue. Patients also undergo blood and urine sample collection. Samples are analyzed for the presence of cancer or changes that indicate that cancer might develop. Patients also undergo colposcopy at baseline and at 3 years. After completion of study procedures, patients are followed every 4 months for up to 3 years. PROJECTED ACCRUAL: A total of 1,150 patients will be accrued for this study.

Arms, Groups and Cohorts

  • HIV+, <CIN2
    • HIV positive women without CIN2-3 or worse
  • HIV-, no >=CIN3 biopsy, HR HPV+
    • HIV negative women without biopsy-proven CIN3 or worse, and with high risk HPV infection
  • HIV-, <=CIN1, HPV- at screening
    • HIV negative women who are <= CIN1 and HPV negative at screening

Clinical Trial Outcome Measures

Primary Measures

  • Identification of hypermethylated genes that are predictive of cervical intraepithelial neoplasia (CIN) grade 3 or invasive cervical cancer
    • Time Frame: 3 years
    • Use molecular assays to identify a panel of hypermethylated genes that are predictive of CIN-3/ICC among women with and without HIV infection. We will rank genes by their ability to discriminate normal cervical tissue from CIN-3/ICC after stratifying by HIV infection.
  • Assessment of the risk of developing CIN3 in relationship to human papillomavirus (HPV) persistence, HIV, and the presence or acquisition of candidate hypermethylated genes
    • Time Frame: 3 years
    • Perform a nested case control study assessing the risk of developing CIN-3 in relationship to HPV persistence, HIV, and the presence or acquisition of the candidate hypermethylated genes.
  • Identification of HIV-related factors associated with the presence or acquisition of specific hypermethylated genes
    • Time Frame: 3 years
    • Identify HIV-related factors (CD4 counts, viral load, HAART) which might be associated with the presence or acquisition of specific hypermethylated genes.

Participating in This Clinical Trial

Inclusion Criteria

  • Underwent Pap smear, human papillomavirus (HPV) testing, and HIV testing AND meets any of the following criteria: – Biopsy and colposcopy confirmed cervical intraepithelial neoplasia (CIN) or invasive cervical cancer (ICC), meeting any of the following criteria: – CIN grade 2-3 or higher – Repeated CIN1 (times 6) – Abnormal Pap smear (atypical squamous cells of undetermined significance [ASCUS] or worse) – HIV seropositive – Negative cytology but positive for high-risk human papillomavirus (HPV) – Negative cytology and negative HPV – HIV negative (without biopsy-proven CIN 3 or worse) and high-risk HPV infection (types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 55, 56, 58, 59, 68, 82, 83, 73) – >= 18 years of age – Intact cervix – Not pregnant – Able to provide informed consent EXCLUSION CRITERIA:
  • < 18 years of age – Pregnant at screening – Cervix not intact – not able to provide informed consent
  • Gender Eligibility: Female

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • University of Washington
    • Collaborator
      • National Cancer Institute (NCI)
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • Nancy B. Kiviat, MD, Principal Investigator, Harborview Injury Prevention and Research Center

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.